Literature DB >> 28948200

Data comparing the plasma levels of procollagen C-proteinase enhancer 1 (PCPE-1) in healthy individuals and liver fibrosis patients.

Eyal Hassoun1, Mary Safrin1, Eitan Wineman1, Peretz Weiss2, Efrat Kessler1.   

Abstract

This article provides a protocol for determination of human procollagen C-proteinase enhancer 1 (PCPE-1) concentrations by ELISA. The inter-assay and intra-assay coefficients of variability are given and so are the average plasma concentrations of PCPE-1 in healthy (control) individuals and liver fibrosis patients.

Entities:  

Keywords:  Collagen biosynthesis; ELISA; Liver fibrosis; biomarkers

Year:  2017        PMID: 28948200      PMCID: PMC5602882          DOI: 10.1016/j.dib.2017.08.047

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of data An ELISA method for determination of procollagen C-proteinase enhancer 1 (PCPE-1) concentrations in human plasma is described. The method can be used for determination of PCPE-1 concentrations in other body fluids. The data highlights the potential of PCPE-1 as a new non-invasive biomarker of liver fibrosis, which could be valuable clinically.

Data

The data includes two Figures and three Tables. Fig. 1 presents a calibration curve for determination of human PCPE-1 concentrations. Table 1, Table 2 provide the plasma concentrations of PCPE-1 in healthy individuals and liver fibrosis patients, respectively. Table 3 summarizes the clinical features of the patients. Fig. 2 compares the average plasma concentrations of PCPE-1 in healthy individuals and liver fibrosis patients. Supplemental Tables S1 and S2 provide raw data used to calculate the inter- and intra-assay coefficients of variability, respectively.
Fig. 1

Standard curve for quantification of huPCPE-1 by sandwich ELISA. Increasing amounts of purified recombinant huPCPE-1 were adsorbed to wells pre-coated with a mouse monoclonal antibody to huPCPE-1. Bound PCPE-1 was detected using a rabbit polyclonal antibody to huPCPE-1 and quantified using an APA-conjugated goat anti rabbit IgG antibody. Each value represents mean±standard deviation (SD); n=2. mOD, Optical Density at 405 nm expressed in milli units.

Table 1

Plasma concentrations of PCPE-1 in healthy (control) individuals.

IndividualGenderAgePCPE-1 plasma concentration(ng/ml±SD)
C1F31312.7±16.5
C2F56339.2±14.4
C3M52317.8±35.1
C4M28285.5±51.1
C5M35329.1±44.4
Mean±SD316.9±20.3a

This value is practically identical to the previously reported [4] value of 305 ng/ml (median; obtained by Western blotting of human sera samples and quantification of PCPE-1 band intensity), supporting the validity of our ELISA. C, control (healthy); F, female; M, male; Age is expressed in years. n=8 (two dilutions, each measured in duplicates on two different days).

Table 2

Plasma concentrations of PCPE-1 in liver fibrosis patients.

PatientGenderAgePCPE-1 plasma concentration(ng/ml±SD)
P1F59342.3±26.9
P2F42618.5±32.1
P3M56433.3±24.7
P4M54299.9±31.0
P5M64546.8±30.1
Mean±SD448.1±134.3

P, patient; F, female; M, male; Age is expressed in years. n=4 (two dilutions each measured in duplicates).

Table 3

Etiology, clinical features and MELD indexes of liver fibrosis patients.

PatientCauseComplicationsAdditional disordersMELD
P1HBVGastropathy, Controlled ascitesHypertension, Obesity, Ovary cancer2
P2HBVEsophageal varicesNone4
P3HCVBleeding varicesDiabetes Mellitus Type 25
P4HBVBleeding varices, Controlled ascites, EncephalopathyDiabetes Mellitus Type 212
P5HCVNoneHypothyroidism9

P, patient; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-stage Liver Disease (a measure of mortality risk in patients with end-stage liver disease; http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease).

Fig. 2

PCPE-1 plasma concentrations in healthy (control) subjects and liver fibrosis patients. Data from Table 1, Table 2 (presented as the mean±standard deviation; n=5).

Standard curve for quantification of huPCPE-1 by sandwich ELISA. Increasing amounts of purified recombinant huPCPE-1 were adsorbed to wells pre-coated with a mouse monoclonal antibody to huPCPE-1. Bound PCPE-1 was detected using a rabbit polyclonal antibody to huPCPE-1 and quantified using an APA-conjugated goat anti rabbit IgG antibody. Each value represents mean±standard deviation (SD); n=2. mOD, Optical Density at 405 nm expressed in milli units. PCPE-1 plasma concentrations in healthy (control) subjects and liver fibrosis patients. Data from Table 1, Table 2 (presented as the mean±standard deviation; n=5). Plasma concentrations of PCPE-1 in healthy (control) individuals. This value is practically identical to the previously reported [4] value of 305 ng/ml (median; obtained by Western blotting of human sera samples and quantification of PCPE-1 band intensity), supporting the validity of our ELISA. C, control (healthy); F, female; M, male; Age is expressed in years. n=8 (two dilutions, each measured in duplicates on two different days). Plasma concentrations of PCPE-1 in liver fibrosis patients. P, patient; F, female; M, male; Age is expressed in years. n=4 (two dilutions each measured in duplicates). Etiology, clinical features and MELD indexes of liver fibrosis patients. P, patient; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-stage Liver Disease (a measure of mortality risk in patients with end-stage liver disease; http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease).

Experimental design, materials and methods

Proteins and antibodies

Human recombinant PCPE-1 (huPCPE-1) was produced in 293-EBNA cells and purified from conditioned culture media as described [1], [2]. Monoclonal antibody 7A11/1 to huPCPE-1 was produced in our laboratory and is available commercially (Sigma, Santa Cruz). Rabbit polyclonal antibody to human recombinant PCPE-1 was prepared in our laboratory and its IgG fraction isolated from the serum using standard protocols. Similar polyclonal antibodies are available commercially (AssayPro, Proteintech etc.) and can be used instead. Alkaline phosphatase (APA) conjugated goat antibody to rabbit IgG, a monoclonal antibody against the Flag peptide (M2), and bovine serum albumin (RIA grade; cat # A7888) were from Sigma.

Experimental design

Experiments were approved by the Sheba Medical Center ethics committee (SMC-9650-12). Five liver cirrhosis patients at ages 42–64 years old and five healthy individuals at ages 28–56 years old were randomly selected. All of the participating individuals provided written informed consent.

Preparation of plasma samples

Blood was drown into plastic Citrate tubes (BD). After one to two hours at room temperature, the tubes were centrifuged (2000g; 15 min; room temperature) and plasma was transferred into Eppendorf tubes. Plasma samples were divided into aliquots and stored at −80 °C until use, avoiding repeated thawing and freezing.

Sandwich ELISA

The ELISA for human PCPE-1 was conducted as previously described [3] with the following modifications: (1) samples contained either known amounts of huPCPE-1 [1] (Fig. 1) or human plasma samples diluted in 5% BSA in PBS (blocking buffer); (2) wells were coated with monoclonal antibody 7A11/1 (5 μg/ml) to capture the antigen; (3) bound huPCPE-1 was detected using rabbit polyclonal antibody to huPCPE-1 (IgG fraction; 0.1 μg/ml); (4) APA-conjugated goat antibody to rabbit IgG (1:2,000) served for quantification of huPCPE-1. As a control, wells were coated with equivalent amounts of monoclonal antibody M2 (vs. the Flag peptide; instead of antibody 7A11/1), in which case, absorbance was identical to that of the blanks (uncoated wells or wells to which no PCPE-1 was added) namely, no PCPE-1 binding was evident.

Statistical analysis

Statistical significance was evaluated using two-tailed independent t-test. P value <0.05 was considered statistically significant.
Subject areaBiology, Biochemistry
More specific subject areaPlasma markers; Tissue Fibrosis
Type of dataTables; Figures
How data was acquiredELISA
Data formatAnalyzed
ExperimentalfactorsMeasurement of PCPE-1 concentrations in human plasma using sandwich ELISA
ExperimentalfeaturesA procedure for determination of human PCPE-1 concentrations by ELISA was developed using a specific monoclonal antibody for immobilization of human PCPE-1 and a polyclonal rabbit antibody against human PCPE-1 for its detection. PCPE-1 concentrations in plasma samples from healthy individuals and liver fibrosis patients were determined using this assay.
Data source locationTel Aviv University, Tel Aviv, Israel
Data accessibilityData is provided within this article
  4 in total

1.  Folding and activity of recombinant human procollagen C-proteinase enhancer.

Authors:  L Moschcovich; S Bernocco; B Font; H Rivkin; D Eichenberger; N Chejanovsky; D J Hulmes; E Kessler
Journal:  Eur J Biochem       Date:  2001-05

2.  Quantification of human serum procollagen C-proteinase enhancer (hsPCPE) glycopattern.

Authors:  Yael Olswang-Kuz; Boaz Liberman; Israel Weiss; Eyal Ramu; Rony Weitzen; Iris Vered; Galia Gat-Yablonski; Efrat Kessler; Yair Anikster; Shlomit Mesilaty-Gross
Journal:  Clin Chim Acta       Date:  2011-05-04       Impact factor: 3.786

3.  Substrate-specific modulation of a multisubstrate proteinase. C-terminal processing of fibrillar procollagens is the only BMP-1-dependent activity to be enhanced by PCPE-1.

Authors:  Catherine Moali; Bernard Font; Florence Ruggiero; Denise Eichenberger; Patricia Rousselle; Vincent François; Ake Oldberg; Leena Bruckner-Tuderman; David J S Hulmes
Journal:  J Biol Chem       Date:  2005-04-15       Impact factor: 5.157

4.  Procollagen C-Proteinase Enhancer 1 (PCPE-1) as a Plasma Marker of Muscle and Liver Fibrosis in Mice.

Authors:  Eyal Hassoun; Mary Safrin; Hana Ziv; Sarah Pri-Chen; Efrat Kessler
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

  4 in total
  1 in total

1.  Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression.

Authors:  Patricia Sansilvestri Morel; Valerie Duvivier; Florence Bertin; Nicolas Provost; Adel Hammoutene; Edwige-Ludiwyne Hubert; Arantxa Gonzalez; Isabelle Tupinon-Mathieu; Valerie Paradis; Philippe Delerive
Journal:  PLoS One       Date:  2022-02-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.